However, in clinical trials, the majority of non-viral gene therapy drugs encoding vascular endothelial growth factor (VEGF165), hepatocyte growth factor (HGF) or basic fibroblast growth factor (bFGF) demonstrated plausible safety profiles with limited efficacy in patients with cardiovascular disease [1,2,3]. This evidence concerns the gene FGF2 and cardiovascular disorder.